Chemical Structure : Elacridar
CAS No.: 143664-11-3
货号: PC-45887Not For Human Use, Lab Use Only.
Elacridar (GF120918, GW-0918) is a potent inhibitor of multidrug resistance (MDR, P-gp) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥1280 | In stock | |
50 mg | ¥1980 | In stock | |
100 mg | ¥2980 | In stock | |
250 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Elacridar (GF120918, GW-0918) is a potent inhibitor of multidrug resistance (MDR, P-gp) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
Elacridar (GF120918, GW-0918) effectively competes with [3H]azidopine for binding P-glycoprotein.
Elacridar (GF120918, GW-0918) restores sensitivity of the tumor to a single dose of doxorubicin in mice; orally bioavailable.
分子量 | 563.6429 | |
分子式 | C34H33N3O5 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo- |
1. Hyafil F, et al. Cancer Res. 1993 Oct 1;53(19):4595-602.
2. den Ouden D, et al. Leukemia. 1996 Dec;10(12):1930-6.
3. Witherspoon SM, et al. Clin Cancer Res. 1996 Jan;2(1):7-12.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright